1 tracked superinvestor hold Rhythm Pharmaceuticals Inc (RYTM), worth $23M combined, led by Stanley Druckenmiller. Smart money is accumulating RYTM as of the latest 13F filings.
Current price
$102.74
-1.8%
1Y
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies…
Market cap
$5.6B
P/E
-26.31
Div yield
0.0%
Revenue YoY
45.8%
Analyst target
$141
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$23M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
+1
1 buying · 0 selling
Smart money is net accumulating RYTM: 1 funds added or opened versus 0 trimming. 1 opened a brand-new position.
Rhythm Pharmaceuticals Inc (RYTM) is held by 1 tracked funds worth $23M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to Stanley Druckenmiller at 0.4% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
This quarter 1 fund opened a brand-new position (Stanley Druckenmiller), with 0 adding and 0 trimming — a net accumulation signal.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| New buy | 0.4% | $23M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
1 insider filed SEC Form 144 for $7M of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Hunter Smith | Officer | 62,774 | $7M | 2026-08-31 |
Which superinvestors own RYTM?
1 tracked funds hold Rhythm Pharmaceuticals Inc (RYTM), the largest being Stanley Druckenmiller (Duquesne Family Office) at 0.4% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling RYTM?
In the most recent 13F quarter, 1 tracked fund added or opened RYTM and 0 trimmed it, including 1 brand-new position.
How much RYTM do tracked funds hold?
Combined disclosed long exposure to RYTM across tracked superinvestors is $23M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.